Barbro Agren

Title: Barbro Agren: Innovator in Neurotoxin Formulations

Introduction

Barbro Agren is a notable inventor based in Mattmar, Sweden. He has made significant contributions to the field of neurotoxin formulations, particularly with his innovative approach to creating stable liquid compositions. His work is characterized by a focus on safety and efficacy, making strides in therapeutic applications.

Latest Patents

Barbro Agren holds a patent for a liquid neurotoxin formulation stabilized with tryptophan or tyrosine. This invention relates to stable liquid neurotoxin formulations that are free of animal proteins. The formulations include a surfactant, an amino acid selected from tryptophan and tyrosine, and a buffer comprising sodium, chloride, and phosphate ions. The pH of these formulations ranges between 5.5 and 8, ensuring stability for up to two months. These compositions are particularly suitable for therapeutic use, allowing for administration to patients to achieve desired therapeutic or aesthetic effects. Additionally, the invention highlights the use of amino acids to protect proteinaceous neurotoxins from degradation in liquid compositions devoid of animal-derived proteins.

Career Highlights

Throughout his career, Barbro Agren has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Ipsen Biopharm Limited and Galderma Holding SA. His experience in these organizations has contributed to his expertise in developing innovative formulations.

Collaborations

Barbro has collaborated with several professionals in his field, including Anders Jarstad and Anna Friis. These collaborations have fostered a productive environment for innovation and development in neurotoxin formulations.

Conclusion

Barbro Agren's contributions to the field of neurotoxin formulations demonstrate his commitment to advancing therapeutic options. His innovative patent reflects a significant step forward in creating safe and effective treatments.